August 26, 2014 – Toronto, Ontario – Matica Enterprises Inc. (CSE: GRF) (“Matica” or the “Company”) is pleased to announce it has signed a definitive agreement with Bellerosa Distributing Ltd. (“Bellerosa”) to exclusively market the full range of GlobalEx tablets for use in Canadian and US horticultural and agricultural industries. Matica will test, and if successful, distribute and market Chlorine Dioxide tablets in the medical marijuana industry for the elimination of mold, biofilm, and pests in controlled growing facilities, eliminating the need for harmful or Health Canada restricted pesticides.
Under the terms of the definitive agreement, Matica has an option to acquire a 60% interest in the joint venture to be formed by Matica and Bellerosa by expending $200,000 over a two year period on the testing and marketing of the tablets. Matica will also issue 10,000,000 Matica shares to Bellerosa. This transaction will be considered a change of business for Matica and will be deemed a Fundamental Change under the policies of the Canadian Securities Exchange (the “CSE”).
Matica Enterprises CEO, Boris Ziger states, “This is a very important step for Matica as it confirms our commitment to the medical marijuana industry. We are striving to make these chlorine dioxide tablets the go-to solution for growers, a true industry standard. As a natural cleaning and sanitizing agent chlorine dioxide has no equal. It can eliminate the need for pesticides and fungicides not only in the medical marijuana industry but across a wide range fields as well. We hope that this will be the beginning of some very exciting times for Matica.”
Matica has been granted a trading halt by the CSE pending the review of the disclosure related to the change of business to the medical marijuana industry. The Company understands the need for a halt at this stage of the implementation of its change of business and, in order to assist the CSE in their review, will file an updated Form 2A reflecting the new businesses. The trading will resume as soon as the CSE has completed its review.
James Tong is a director of Bellerosa, and his brother, Richard Tong, is the CFO of Matica. The terms of the definitive agreement were negotiated at arm’s length by Bellerosa and Matica.
ABOUT GLOBALEX GROUP
GlobalEx Group is the leading tablets manufacturer to generate Chlorine Dioxide (ClO2) on demand, they created several lines of products in respond to a wide range of applications, decontamination, disinfection and sterilization for civil sectors an industries, including wastewater treatment, drinking water treatment, swimming pools, food and beverage processing, oil industry, reverse osmosis, odour control, water and environmental sanitation, hospitals, agriculture, air purification and prevention of epidemic diseases.
GlobalEx has over 30 patents on their tablets that have NSF and FDA approvals, currently market and use in many areas around the world. The tablets offer a modern, permanent, effective and safe solution for the environment with low capital costs and are available for sale in over 25 different countries worldwide and have pending agreements in 10 more countries. For more information on GlobalEx Group and their products, please visit www.globalex-world.com.
ABOUT MATICA ENTERPRISES INC.
Matica has an exclusive agreement to market GlobalEx Chlorine Dioxide tablets for use as a natural cleaning and sanitizing product for growing Medical Marijuana without the use of pesticides or fungicides. Matica is further exploring opportunities in the medical marijuana and industrial hemp industries and has currently signed two Letters of Intent establishing joint ventures with two separate advanced marijuana growing facilities in BC and Ontario. Matica has graphite projects in Buckingham, Quebec, an historic graphite producing area which has been the scene of renewed exploration activity. For more information on Matica Enterprises please visit the website at: www.maticaenterprises.com.
On behalf of the Board of Directors
MATICA ENTERPRISES INC.
Boris Ziger, CEO & Chairman
Cautionary Note Regarding Forward-Looking Statements
Certain information in this press release may constitute forward-looking information. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in the Company’s filings with the Canadian Securities Regulators, which filings are available at www.sedar.com and www.thecse.com.